在患有喘的儿科患者中提高肺炎球菌疫苗疗效:研究免疫应答调节
Rebekah Brawley1, Andrea Espina Rey1, Aledie Navas Nazario2
1College of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
在患有喘的儿童中,肺炎球菌增强疫苗显示出强大的初始保护,并改善了喘控制. 然而,随着时间的推移,免疫力会减弱,这表明在这个高危人群中需要优化疫苗接种计划.
科学领域:
- 儿科肺病学 儿科肺病学
- 传染病免疫学 传染病免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 儿童喘患者面临侵袭性肺炎球菌疾病的风险更高.
- 对于患有喘的儿童来说,最佳的肺炎球菌疫苗接种策略,特别是强剂量,尚未明确定义.
- 了解这种人群中的疫苗有效性对于公共卫生至关重要.
研究的目的:
- 评估儿童喘患者对肺炎球菌再接种疫苗的血清反应.
- 评估疫苗接种后的临床结果,包括喘严重程度和类固醇使用.
- 为了研究在增强剂后免疫保护的持久性.
主要方法:
- 64名接受肺炎球菌增强剂的儿科喘患者 (2-17岁) 的回顾性图表审查.
- 收集了有关人口统计,喘严重程度,全身类固醇使用和疫苗标位的数据.
- 分析了喘分类和类固醇使用在接种疫苗前后的变化.
主要成果:
- 96.9%的人在接种疫苗后4-8周获得了保护性抗体标位.
- 6个月后,71.4%的人失去了保护位,这表明免疫力下降.
- 疫苗接种后观察到喘严重程度 (p<0.001) 和全身类固醇使用 (p<0.001) 的显著降低.
结论:
- 肺炎球菌增强疫苗接种提供了初始的免疫保护,并改善了儿童的喘结果.
- 免疫力下降需要进一步研究最佳的疫苗计划和增强剂的时间.
- 研究免疫调节疗法对疫苗反应的影响至关重要.
更多相关视频
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Nursing Management
First, in...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction
